LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
LivaNova PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$78.14+0.56 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $4.40B
- P/E (TTM)
- 23.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
67.7%+4.0 pts over 5 years
Operating margin
14.4%+43.7 pts over 5 years
Net margin
-17.5%+19.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10.7% | +10.8% | +8.2% | +16.9% | |
| Gross profit | +10.1% | +9.9% | +9.6% | +13.5% | |
| Operating income | +54.5% | – | – | +8.4% | |
| Free cash flow | +27.5% | +58.6% | – | +9.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 21.6% | -28.0% | -19.2% | |
| Return on assets | 19.0% | -14.5% | -9.5% | |
| Current ratio | 7.65 | 2.29 | 1.36 | |
| Debt to equity | 0.00 | 0.59 | 0.31 | |
| Interest coverage | 4221.5× | -6.7× | 4.0× | |
| Inventory turnover | 1.3× | 2.4× | 2.9× | |
| Capex to revenue | 2.3% | 3.7% | 5.8% | |
| Diluted shares | 27M | 49M | 55M |
Where the cash went
Fiscal 2021 to 2025, five years combined
LivaNova generated $684.76M from operations and spent $215.13M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$684.76M
Used
$215.13M
Capital expenditure$215.13M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-17.5%
×Asset turnover0.54×
×Equity multiplier2.03×
=Return on equity, FY2025-19.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -17.5% | 0.54× | 2.03× | -19.2% |
| FY2024 | 5.0% | 0.51× | 1.90× | 4.9% |
| FY2023 | 1.5% | 0.49× | 1.90× | 1.4% |
| FY2022 | -8.4% | 0.45× | 1.80× | -6.9% |
| FY2021 | -13.1% | 0.45× | 1.91× | -11.3% |
| FY2020 | -37.3% | 0.39× | 1.93× | -28.0% |
| FY2019 | -14.5% | 0.44× | 1.72× | -11.0% |
| FY2018 | -17.1% | 0.44× | 1.52× | -11.4% |
| FY2015 | 19.8% | 0.96× | 1.14× | 21.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$242.47M
- Cash generatingOperating cash flow above zero$254.34M
- Return on assets improvedROA up on the prior year2.6% → -9.7%
- Earnings backed by cashOperating cash flow above net income$254.34M vs -$242.47M
- Less leverageLong-term debt to assets fell21.9% → 13.2%
- Better liquidityCurrent ratio rose2.87 → 1.36
- No dilutionShare count did not rise55M → 55M
- Gross margin improvedGross margin up on the prior year68.09% → 67.71%
- More efficientAsset turnover rose0.52 → 0.55